Sales in Q4 came in slightly higher than our forecast. The outcome, combined with lower-than-expected operating costs, resulted in an EBITDA that exceeded our expectations. With obtained CPT codes and progression according to plan in the research portfolio, Xvivo Perfusion is poised for a strong 2018. Our fair value remains unchanged at SEK 105 per share.